Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncology CER Needs Common Language, Data Collection Standards

Executive Summary

Several articles in a comparative effectiveness research-themed issue of the Journal of Clinical Oncology highlight the need for CER to use common language and data collection standards to boost the value and usefulness of the research.

You may also be interested in...

Health Technology Assessments Should Help Prioritize CER – Journal Authors

While health technology assessment’s role primarily is to aid clinical and policy decision-making, it also has the potential to help prioritize the comparative effectiveness research agenda as well as inform trial designs, according to a recent article in the Journal of Clinical Oncology.

E-Health Records Not Ready For Prime Time In Research, Disparities In Adoption Suggest

Researchers looking to use electronic health records may have to wait a bit longer before EHRs become a viable tool for comparative effectiveness research, based on disparities in the location of EHR adoption. A GAO report finds the highest adoption of EHRs in the South and in urban areas.

Accelerated Approval Could Spur Development Of Patient-Reported Outcomes Tools

A subtle takeaway from the Oncologic Drugs Advisory Committee’s March 20 review of GlaxoSmithKline’s Votrient (pazopanib) for treatment of advanced soft tissue sarcoma was that accelerated approval, with a post-marketing requirement to confirm clinical benefit in a difficult-to-treat population, could incentivize sponsors to develop instruments for assessing symptom improvement.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts